Related Experiment Video
Updated: Jul 8, 2025
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
INTRAVITREAL FARICIMAB AS AN ADJUVANT IN THE MANAGEMENT OF TUBERCULAR UVEITIS
Yasmine Alcibahy1,2, Karina Julian2, Maria Fernanda Bonilla3
1Royal College of Surgeons in Ireland - Medical University of Bahrain (RCSI-MUB), Al Sayh Muharraq Governorate, Bahrain.
Purpose:
The objective of this study was to report the use of intravitreal faricimab used as an adjunct in the management of intraocular tuberculosis in a patient with occlusive retinal vasculitis and choroiditis.
Methods:
This is a case report.
Results:
A 27-year-old Asian man presented with bilateral choroiditis and occlusive retinal vasculitis complicated by retinal neovascularization and vitreous hemorrhage in one eye. The patient had a positive tuberculin skin test, indeterminate interferon-gamma release assay, and Ghon focus on chest radiography. With a diagnosis of intraocular tuberculosis, the patient was treated with antitubercular therapy. Owing to the significant vitreous hemorrhage, he underwent pars plana vitrectomy in one eye. The patient received bilateral faricimab. Within a week of the injection, he had a near-complete resolution of the extensive choroidal and retinal vascular inflammation.
Conclusion:
Intravitreal faricimab, given its angiopoietin-2 inhibition and antivascular endothelial growth factor action, maybe a helpful adjunct in intraocular tuberculosis. Whether angiopoietin-2 inhibition provides any additional benefit needs further evaluation in extensive studies.
